Sphingolipid paracrine signaling impairs keratinocyte adhesion to promote melanoma invasion

Autor: Justine Noujarède, Lorry Carrié, Virginie Garcia, Maxime Grimont, Anaïs Eberhardt, Elodie Mucher, Matthieu Genais, Anne Schreuder, Stéphane Carpentier, Bruno Ségui, Laurence Nieto, Thierry Levade, Susana Puig, Teresa Torres, Josep Malvehy, Olivier Harou, Jonathan Lopez, Stéphane Dalle, Julie Caramel, Laure Gibot, Joëlle Riond, Nathalie Andrieu-Abadie

Publikováno v: Cell Reports, Vol 42, Iss 12, Pp 113586- (2023)

Summary: Melanoma is the deadliest form of skin cancer due to its propensity to metastasize. It arises from melanocytes, which are attached to keratinocytes within the basal epidermis. Here, we hypothesize that, in addition to melanocyte-intrinsic mo

Externí odkaz: https://doaj.org/article/ef232163d25a461ab0d0fdfe5ad159f7

Data from Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas

Autor: Nathalie Andrieu-Abadie, Corine Bertolotto, Thierry Levade, Jean-Christophe Marine, Bruno Ségui, Sophie Tartare-Deckert, Silvia Arcucci, Stéphanie Brayer, Nicolas Meyer, Thomas Filleron, Julia Gilhodes, Florian Rambow, Marie-Lise Bats, Virginie Garcia, Caroline Imbert, Justine Leclerc, Justine Noujarède, David Garandeau

BRAF inhibitors (BRAFi) are used to treat patients with melanoma harboring the V600E mutation. However, resistance to BRAFi is inevitable. Here, we identified sphingosine 1-phosphate (S1P) receptors as regulators of BRAFV600E-mutant melanoma cell-aut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::55aa499de44299c704a27fa4b25b7064
https://doi.org/10.1158/1535-7163.c.6538816.v1

Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas

Autor: Silvia Arcucci, Sophie Tartare-Deckert, Corine Bertolotto, Justine Noujarède, Florian Rambow, Thierry Levade, Nathalie Andrieu-Abadie, Julia Gilhodes, Caroline Imbert, Stéphanie Brayer, Thomas Filleron, Nicolas Meyer, Jean-Christophe Marine, Bruno Ségui, Marie-Lise Bats, Virginie Garcia, Justine Leclerc, David Garandeau

Publikováno v: Molecular Cancer Therapeutics
Molecular Cancer Therapeutics, American Association for Cancer Research, 2019, 18 (2), pp.289-300. ⟨10.1158/1535-7163.MCT-17-1141⟩

BRAF inhibitors (BRAFi) are used to treat patients with melanoma harboring the V600E mutation. However, resistance to BRAFi is inevitable. Here, we identified sphingosine 1-phosphate (S1P) receptors as regulators of BRAFV600E-mutant melanoma cell-aut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::779a882eb0d91f1f52243d3107aa5d1d
https://doi.org/10.1158/1535-7163.mct-17-1141